Literature DB >> 10991835

Evaluation of nitrofurantoin combination therapy of metronidazole-sensitive and -resistant Helicobacter pylori infections in mice.

P J Jenks1, R L Ferrero, J Tankovic, J M Thiberge, A Labigne.   

Abstract

The main objectives of this study were to determine whether the nitroreductase enzyme encoded by the rdxA gene of Helicobacter pylori was responsible for reductive activation of nitrofurantoin and whether a triple-therapy regimen with nitrofurantoin was able to eradicate metronidazole-sensitive and -resistant H. pylori infections from mice. The susceptibilities to nitrofurantoin of parent and isogenic rdxA mutant strains (three pairs), as well as a series of matched metronidazole-sensitive and -resistant strains isolated from mice (30) and patients (20), were assessed by agar dilution determination of the MIC. Groups of mice colonized with the metronidazole-sensitive H. pylori SS1 strain or a metronidazole-resistant rdxA SS1 mutant were treated with either metronidazole or nitrofurantoin as part of a triple-therapy regimen. One month after the completion of treatment the mice were sacrificed and their stomachs were cultured for H. pylori. The nitrofurantoin MICs for all strains tested were between 0.5 and 4.0 microg/ml. There was no significant difference between the susceptibility to nitrofurantoin of the parental strains and those of respective rdxA mutants or between those of matched metronidazole-sensitive and -resistant H. pylori isolates. The regimen with metronidazole eradicated infection from all eight SS1-infected mice and from one of eight mice inoculated with the rdxA mutant (P < or =0.001). The regimen with nitrofurantoin failed to eradicate infection from any of the six SS1-infected mice (P < or =0.001) and cleared infection from one of seven mice inoculated with the rdxA mutant. These results demonstrate that, despite the good in vitro activity of nitrofurantoin against H. pylori and the lack of cross-resistance between metronidazole and nitrofurantoin, eradication regimens involving nitrofurantoin are unable to eradicate either metronidazole-sensitive or -resistant H. pylori infections from mice.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10991835      PMCID: PMC90126          DOI: 10.1128/AAC.44.10.2623-2629.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  55 in total

1.  [A therapeutic trial in Giardia muris infection in the mouse with metronidazole, tinidazole, secnidazole and furazolidone].

Authors:  C C Cruz; L Ferrari; R Sogayar
Journal:  Rev Soc Bras Med Trop       Date:  1997 May-Jun       Impact factor: 1.581

Review 2.  Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group.

Authors: 
Journal:  Gut       Date:  1997-07       Impact factor: 23.059

3.  The reduction of Furacin by cell-free extracts of Furacin-resistant and parent-susceptible strains of Escherichia coli.

Authors:  R E ASNIS
Journal:  Arch Biochem Biophys       Date:  1957-01       Impact factor: 4.013

4.  The complete genome sequence of the gastric pathogen Helicobacter pylori.

Authors:  J F Tomb; O White; A R Kerlavage; R A Clayton; G G Sutton; R D Fleischmann; K A Ketchum; H P Klenk; S Gill; B A Dougherty; K Nelson; J Quackenbush; L Zhou; E F Kirkness; S Peterson; B Loftus; D Richardson; R Dodson; H G Khalak; A Glodek; K McKenney; L M Fitzegerald; N Lee; M D Adams; E K Hickey; D E Berg; J D Gocayne; T R Utterback; J D Peterson; J M Kelley; M D Cotton; J M Weidman; C Fujii; C Bowman; L Watthey; E Wallin; W S Hayes; M Borodovsky; P D Karp; H O Smith; C M Fraser; J C Venter
Journal:  Nature       Date:  1997-08-07       Impact factor: 49.962

Review 5.  Choosing the best anti-Helicobacter pylori therapy: effect of antimicrobial resistance.

Authors:  D Y Graham; W A de Boer; G N Tytgat
Journal:  Am J Gastroenterol       Date:  1996-06       Impact factor: 10.864

6.  Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection.

Authors:  A M Segura; O Gutiérrez; W Otero; A Angel; R M Genta; D Y Graham
Journal:  Aliment Pharmacol Ther       Date:  1997-06       Impact factor: 8.171

Review 7.  Helicobacter pylori: microbiology of a 'slow' bacterial infection.

Authors:  M J Blaser
Journal:  Trends Microbiol       Date:  1993-10       Impact factor: 17.079

8.  Multiple strain colonization and metronidazole resistance in Helicobacter pylori-infected patients: identification from sequential and multiple biopsy specimens.

Authors:  M Jorgensen; G Daskalopoulos; V Warburton; H M Mitchell; S L Hazell
Journal:  J Infect Dis       Date:  1996-09       Impact factor: 5.226

9.  A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain.

Authors:  A Lee; J O'Rourke; M C De Ungria; B Robertson; G Daskalopoulos; M F Dixon
Journal:  Gastroenterology       Date:  1997-04       Impact factor: 22.682

10.  Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection.

Authors:  A W Harris; D I Pryce; S M Gabe; Q N Karim; M M Walker; H Langworthy; J H Baron; J J Misiewicz
Journal:  Aliment Pharmacol Ther       Date:  1996-12       Impact factor: 8.171

View more
  8 in total

1.  In vitro and in vivo activities of Chios mastic gum extracts and constituents against Helicobacter pylori.

Authors:  Sotirios Paraschos; Prokopios Magiatis; Sofia Mitakou; Kalliopi Petraki; Antonios Kalliaropoulos; Petros Maragkoudakis; Andreas Mentis; Dionyssios Sgouras; Alexios-Leandros Skaltsounis
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

2.  Who's Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori.

Authors:  Kathleen R Jones; Jeong-Heon Cha; D Scott Merrell
Journal:  Curr Drug ther       Date:  2008-09-01

3.  Differentiation of metronidazole-sensitive and -resistant clinical isolates of Helicobacter pylori by immunoblotting with antisera to the RdxA protein.

Authors:  S R Latham; R J Owen; N C Elviss; A Labigne; P J Jenks
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

4.  Coating nanoparticles with gastric epithelial cell membrane for targeted antibiotic delivery against Helicobacter pylori infection.

Authors:  Pavimol Angsantikul; Soracha Thamphiwatana; Qiangzhe Zhang; Kevin Spiekermann; Jia Zhuang; Ronnie H Fang; Weiwei Gao; Marygorret Obonyo; Liangfang Zhang
Journal:  Adv Ther (Weinh)       Date:  2018-05-08

5.  Gastric transitional zones, areas where Helicobacter treatment fails: results of a treatment trial using the Sydney strain mouse model.

Authors:  Sander J O Veldhuyzen van Zanten; Tassia Kolesnikow; Vincent Leung; Jani L O'Rourke; Adrian Lee
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

6.  Helicobacter pylori mutants defective in RuvC Holliday junction resolvase display reduced macrophage survival and spontaneous clearance from the murine gastric mucosa.

Authors:  Michael F Loughlin; Faye M Barnard; David Jenkins; Gary J Sharples; Peter J Jenks
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

7.  Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori.

Authors:  Gary Sisson; Avery Goodwin; Ausra Raudonikiene; Nicky J Hughes; Asish K Mukhopadhyay; Douglas E Berg; Paul S Hoffman
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

8.  Targeting of Helicobacter pylori thymidylate synthase ThyX by non-mitotoxic hydroxy-naphthoquinones.

Authors:  Stéphane Skouloubris; Kamel Djaout; Isabelle Lamarre; Jean-Christophe Lambry; Karine Anger; Julien Briffotaux; Ursula Liebl; Hilde de Reuse; Hannu Myllykallio
Journal:  Open Biol       Date:  2015-06       Impact factor: 6.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.